HSF1 — Heat Shock Factor 1
<div class="infobox infobox-protein">
<table>
<tr><th>Protein Name</th><td>Heat Shock Factor 1</td></tr>
<tr><th>Gene</th><td>HSF1</td></tr>
<tr><th>UniProt ID</th><td><a href="https://www.uniprot.org/uniprot/Q00613">Q00613</a></td></tr>
<tr><th>PDB IDs</th><td>5D5U, 5N5W</td></tr>
<tr><th>Molecular Weight</th><td>53 kDa</td></tr>
<tr><th>Subcellular Localization</th><td>Cytoplasm (inactive), Nucleus (active)</td></tr>
<tr><th>Protein Family</th><td>HSF transcription factor family</td></tr>
</table>
</div>
Overview
HSF1 (Heat Shock Factor 1) is the master transcriptional regulator of the cellular proteotoxic stress response. It controls expression of the major molecular chaperones—HSP70 (HSPA1A/B), HSP90, HSP27, and HSP40—that maintain protein homeostasis by assisting in folding, preventing aggregation, and targeting misfolded proteins for degradation. In non-stressed cells, HSF1 exists as an inactive monomer bound to HSP90 and other chaperones. Upon heat, oxidative stress, or accumulation of misfolded proteins, released HSF1 trimerizes, undergoes activating phosphorylation at multiple serine residues (Ser230, Ser326, Ser419), and translocates to the nucleus where it binds heat shock elements (HSEs, nGAAn repeats) to drive chaperone gene transcription[^1].
...HSF1 — Heat Shock Factor 1
<div class="infobox infobox-protein">
<table>
<tr><th>Protein Name</th><td>Heat Shock Factor 1</td></tr>
<tr><th>Gene</th><td>HSF1</td></tr>
<tr><th>UniProt ID</th><td><a href="https://www.uniprot.org/uniprot/Q00613">Q00613</a></td></tr>
<tr><th>PDB IDs</th><td>5D5U, 5N5W</td></tr>
<tr><th>Molecular Weight</th><td>53 kDa</td></tr>
<tr><th>Subcellular Localization</th><td>Cytoplasm (inactive), Nucleus (active)</td></tr>
<tr><th>Protein Family</th><td>HSF transcription factor family</td></tr>
</table>
</div>
Overview
HSF1 (Heat Shock Factor 1) is the master transcriptional regulator of the cellular proteotoxic stress response. It controls expression of the major molecular chaperones—HSP70 (HSPA1A/B), HSP90, HSP27, and HSP40—that maintain protein homeostasis by assisting in folding, preventing aggregation, and targeting misfolded proteins for degradation. In non-stressed cells, HSF1 exists as an inactive monomer bound to HSP90 and other chaperones. Upon heat, oxidative stress, or accumulation of misfolded proteins, released HSF1 trimerizes, undergoes activating phosphorylation at multiple serine residues (Ser230, Ser326, Ser419), and translocates to the nucleus where it binds heat shock elements (HSEs, nGAAn repeats) to drive chaperone gene transcription[^1].
In the context of neurodegeneration, HSF1 is particularly critical because post-mitotic neurons depend on chaperone systems rather than cell division to dilute misfolded proteins. Moreover, HSF1 activity declines with aging—the period of highest neurodegeneration risk—creating a proteostasis deficit insufficient to handle the aggregation-prone proteins central to disease (amyloid-β, tau, α-synuclein, SOD1, TDP-43, huntingtin)[^2].
Mechanism of Action in Neurodegeneration
The relevance of HSF1 to neurodegeneration stems from the observation that essentially every major aggregation-prone disease protein is a substrate for HSP70/HSP90 chaperone systems. When chaperone capacity is exceeded, these clients misfold and aggregate. In a vicious cycle, protein aggregates sequester HSP70 and other chaperones, further reducing cellular proteostasis capacity[^3].
HSF1 loss creates a permissive environment for tau accumulation and hyperphosphorylation. A 2017 study showed a bidirectional interplay: HSF1 degradation (via CHIP-mediated ubiquitination, which is redirected from tau to HSF1 when tau is abundant) promotes tau hyperphosphorylation, while tau hyperphosphorylation further destabilizes HSF1, creating a feedforward collapse of the proteostasis network in tauopathies. PMID: 28678786 This CHIP competition model explains why overexpression of CHIP or HSF1 reduces tau pathology[^4].
For α-synuclein pathology, HSF1 activity is protective through multiple mechanisms. First, HSP70 and HSP90 directly interact with soluble α-synuclein and prevent its aggregation into toxic oligomers. Second, HDAC6, which is induced by HSF1, traffics misfolded proteins to aggresomes for autophagic degradation. In a dopaminergic neuron model, HSF1 induction by HDAC6 activation reduced cytotoxic α-synuclein accumulation and protected against cell death. PMID: 24866403 Third, HSF1-driven HSP70 expression suppresses mitophagy defects in PINK1/Parkin mutant dopaminergic neurons[^5].
In ALS, HSF1 activation is protective against both mutant SOD1 aggregation and TDP-43/FUS pathology. HSP90, which HSF1 also upregulates, maintains FUS and TDP-43 in their soluble nuclear compartment and its dysfunction accelerates their cytoplasmic mislocalisation. PMID: 41767843[^6]
HSF1 is also required for synaptic fidelity at neuromuscular junctions and for hippocampal memory consolidation, suggesting its role extends beyond emergency stress response to ongoing maintenance of synaptic proteomes. PMID: 27283588[^7]
Key Experimental Evidence
Tau and HSF1 competition for CHIP: HSF1 and tau compete for the chaperone E3 ligase CHIP. In the setting of elevated tau, CHIP is redirected to ubiquitinate and degrade HSF1, depleting the transcription factor. HSF1 depletion reduces HSP expression, further impairing tau clearance. CHIP overexpression breaks this cycle by restoring HSF1 levels and reducing tau burden in mouse tauopathy models. PMID: 28678786[^8]
p53-HSF1 axis in Huntington's disease: A 2023 study showed that tumor suppressor p53, which is activated in Huntington's disease neurons, promotes HSF1 ubiquitination and degradation via specific E3 ligases, revealing a previously unknown p53-dependent mechanism of HSF1 depletion in neurodegeneration. Blocking this interaction in HD cell models restored HSF1 levels and reduced huntingtin aggregate burden. PMID: 36867535
HDAC6-HSF1-α-synuclein axis: HDAC6 activity protects against α-synuclein toxicity in dopaminergic cells by inducing HSF1-dependent chaperone expression and aggresome formation. HDAC6 inhibition or HSF1 knockdown both increased soluble toxic α-synuclein oligomers, validating the HSF1-HDAC6 axis as a protective pathway in PD. PMID: 24866403
HSP90 in Parkinson's disease: HSP90, an HSF1-regulated chaperone, is elevated in the brains of PD patients and shows a dual role: normally facilitating LRRK2 stability, but upon α-synuclein accumulation redirecting to α-synuclein chaperoning at the expense of other clients. PMID: 38040085
Novel chaperone activators for neurodegeneration: A 2025 screen identified novel small-molecule HSF1 activators that induce proteostasis machinery selectively in neurons without the broad cytotoxic effects of HSP90 inhibitors, representing a more targeted therapeutic approach. PMID: 40239269
Current Therapeutic Targeting Strategies
| Strategy | Agent | Mechanism | Stage |
|----------|-------|-----------|-------|
| HSP90 inhibition | 17-AAG (tanespimycin), ganetespib | Releases HSF1 from HSP90 inhibition | Phase I/II (cancer); preclinical (neuro) |
| Direct HSF1 activation | Celastrol, HSF1A, geranylgeranylacetone | Direct HSF1 activators | Preclinical |
| HDAC6 inhibition | Tubastatin A, ricolinostat | Induces HSF1 and aggresome pathway | Phase I/II (cancer); preclinical (neuro) |
| Chaperone induction | Novel small molecules | Selective HSF1 activation in neurons | Preclinical PMID: 40239269 |
| NRF2/HSF1 co-activation | Dimethyl fumarate | Dual proteostasis and antioxidant | FDA-approved (MS), being studied in PD/ALS |
A key challenge in HSF1 therapeutics is the narrow therapeutic window: insufficient activation fails to restore proteostasis, while excessive activation promotes HSP90's role as a client-stabilizing oncoprotein in cancer. Neuron-specific or conditional HSF1 activation strategies are therefore prioritized for neurodegeneration applications.
Open Questions and Knowledge Gaps
- Whether HSF1 decline in aging is a cause or consequence of proteostasis deterioration in the aging brain
- How to achieve neuron-selective HSF1 activation without pro-oncogenic effects in peripheral tissues
- The relative contributions of HSF1-driven transcription vs. HSF1's non-transcriptional functions to neuroprotection
- Whether plasma biomarkers of chaperone activity (e.g., extracellular HSP70 levels) could serve as surrogates for HSF1 activity in clinical trials
- The relationship between HSF1 and sleep-mediated glymphatic protein clearance, both of which decline in aging
Related Pages
- [HSP70 (HSPA1A)](/proteins/hsp70)
- [HSP90](/proteins/hsp90)
- [CHIP (STUB1)](/proteins/stub1)
- [Proteostasis in Neurodegeneration](/mechanisms/proteostasis-neurodegeneration)
References
[^1]: Unknown et al. Cold exposure impairs the muscle growth-promoting effect of nighttime-restricted feeding by desynchronizing mitochond.... J Therm Biol. 2026. PMID:41941843.
[^2]: Unknown et al. FAK/SRC-JNK axis promotes ferroptosis via upregulating ACSL4 expression.. Cell death & disease. 2026. PMID:41862445.
[^3]: Unknown et al. Paeoniflorin Attenuates Oxidative Stress and Inflammation in Parkinson's Disease by Activating the HSF1-NRF1 Axis.. The American journal of Chinese medicine. 2024. PMID:39663263.
[^4]: Yi-Fu et al. HSF1 Alleviates Brain Injury by Inhibiting NLRP3-Induced Pyroptosis in a Sepsis Model.. Mediators of inflammation. 2023. PMID:36741074.
[^5]: Unknown et al. HDAC6 as privileged target in drug discovery: A perspective.. Pharmacological research. 2021. PMID:33171304.
[^6]: Unknown et al. Receptor-interacting protein 140 as a co-repressor of Heat Shock Factor 1 regulates neuronal stress response.. Cell death & disease. 2017. PMID:29233969.
[^7]: Unknown et al. Cold exposure impairs the muscle growth-promoting effect of nighttime-restricted feeding by desynchronizing mitochond.... J Therm Biol. 2026. PMID:41941843.
[^8]: Unknown et al. FAK/SRC-JNK axis promotes ferroptosis via upregulating ACSL4 expression.. Cell death & disease. 2026. PMID:41862445.